TapClicks, Inc., a San Jose, CA-based marketing technology company, received a $3m credit facility from SaaS Capital.
REG (UK) Ltd, a London, UK-based online counterparty risk management platform for the UK general insurance market, received an £8m majority investment from Disruptive Capital Investments Ltd.
YourWelcome, a London, UK-based provider of a tablet for vacation rentals & short-term lets, raised £1m in seed funding.
AccessPay, a Manchester, UK-based fintech company, raised £2m in debt financing.
Lifescale Limited, a London, UK-based consumer risk management platform, received an angel investment from Cristóbal Conde.
Domo, an American Fork, UT-based provider of a business optimization platform, closed $100m in a Series D2 extension financing.
Lynk, a Hong Kong-based SaaS platform that connects enterprise users to experts in a variety of areas, raised US$4m in series A funding.
dpixel, the advisor of startup investment fund Barcamper Ventures, has launched the second call for its acceleration program.
Satispay, a Milan, Italy-based fintech startup, raised €14m in its latest funding round.
Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at €64.75m (USD68.5m).
Snow Software, a Solna, Stockholm, Sweden-based provider of Software Asset Management and Cloud Spend Management solutions, received a $120m strategic investment.
Popular US venture capitalist Chris Sacca, known for his early investments in Twitter and Uber, and the recent exit from Twilio, is retiring from startup investing.
Cubigo, a Hasselt, Belgium-based personal platform to access a wide range of services dedicated to independent living, raised €4m in funding.
U.S. venture capital (VC) investment in fintech companies rose to $1.2 billion in Q1’17, driven by late-stage deals, which reached the highest activity since Q1’16, according to KPMG International’s Q1 2017 The Pulse of Fintech report.
Epic Sciences, a San Diego, CA-based developer of liquid biopsy tests to predict drug response in cancer patients, completed a $40m Series D financing.